[1,4]Diazepan-1-yl-furan-2-yl-methanone | 61903-13-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [1,4]Diazepan-1-yl-furan-2-yl-methanone
• 英文别名: N-(furan-2-carbonyl)-1,4-diazepane；N-(2-Furoyl)-homopiperazin；N-(2-Furoyl)-homopiperazine；1-(2-furoyl)homopiperazine；1-(2-furoyl)-hexahydro-1,4-diazepine；(1,4-Diazepan-1-yl)(furan-2-yl)methanone；1,4-diazepan-1-yl(furan-2-yl)methanone
• CAS: 61903-13-7
• 化学式: C₁₀H₁₄N₂O₂
• mdl: MFCD09049715
• 分子量: 194.233
• InChiKey: SDTBJQANMVJMSP-UHFFFAOYSA-N

物化性质

• 沸点：
  335.1±32.0 °C(Predicted)
• 密度：
  1.135±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  [1,4]Diazepan-1-yl-furan-2-yl-methanone 在 铑 作用下， 以 乙醇 为溶剂， 以to give the desired product, B.P. 135° at 1 mm的产率得到1,4-二氮杂环庚-1-基(四氢-2-呋喃基)甲酮
  参考文献：
  名称：

  Chloro- and alkoxy-substituted-2,4-diaminoquinazolines

  摘要：

  该专利描述了式子##STR1##中Y.sup.1是氢或氯，Y.sup.2是OR，Y.sup.3是氢或OR，当Y.sup.1是氢时，Y.sup.3是OR，当Y.sup.1是氯时，Y.sup.3是氢或OR。其中R代表一个由一个到三个碳原子组成的烷基；R.sup.1和R.sup.2分别为氢、由一个到五个碳原子组成的烷基、由三到八个碳原子组成的环烷基、由三到五个碳原子组成的烯基或炔基或在有机取代的情况下，为由两个到五个碳原子组成的羟基取代的烷基。当它们与它们所连接的氮原子一起取代时，R.sup.1和R.sup.2形成一个取代或未取代的杂环基，该杂环基可以选择性地包含一个氧原子、硫原子或第二个氮原子作为环成员。该专利还涉及这些化合物作为降压剂的用途，包含它们的制药组合物以及它们的中间体的生产。

  公开号：

  US04377581A1
• 作为产物：
  描述：

  1,4-二氮杂环庚烷-1-甲酸叔丁酯 在 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 [1,4]Diazepan-1-yl-furan-2-yl-methanone
  参考文献：
  名称：

  Synthesis, Cytotoxicity Evaluation, and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands

  摘要：

  Among several potential applications, sigma receptor ligands can be used as antipsychotics, antiamnesics, and against other neurodegenerative disorders as well as neuroprotective agents. We present herein a new series of diazepane-containing derivatives as sigma R ligands obtained by a conformational expansion approach of our previously synthesized piperidine-based compounds. The best results were reached by benzofurane 2c, 3c and quinoline 2d, 3d-substituted diazepane derivatives, which showed the highest sigma R affinity. The cytotoxic activities of synthesized compounds were evaluated against two cancer cell lines, and the results indicated that none of the compounds induced significant toxicity in these cells. We also evaluated the antioxidant activity by radical scavenging capacity of our best compounds on ABTS and H2O2. The results obtained reveal that our new derivatives possess an excellent antioxidant profile and could be protective for the cells. Overall, the benzofurane derivative 2c due to its strong interaction with the active site of the receptor, as confirmed by molecular dynamic simulations, emerged as the optimum compound with high sigma 1R affinity, low cytotoxicity, and a potent antioxidant activity.

  DOI：

  10.1021/acsmedchemlett.9b00524

文献信息

• Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
  申请人：Pfizer Inc.

  公开号：US04287341A1

  公开（公告）日：1981-09-01

  2,4-Diaminoquinazolines of the formula ##STR1## wherein Y.sup.1 is hydrogen or chloro, Y.sup.2 is OR, Y.sup.3 is hydrogen or OR such that when Y.sup.1 is hydrogen, Y.sup.3 is OR and when Y.sup.1 is chloro, Y.sup.3 is hydrogen or OR, and the pharmaceutically acceptable salts thereof; R represents an alkyl group having from one to three carbon atoms; taken separately, R.sup.1 and R.sup.2 are each hydrogen, alkyl having from one to five carbon atoms, cycloalkyl having from three to eight carbon atoms, alkenyl or alkynyl each having from three to five carbon atoms or hydroxy substituted alkyl having from two to five carbon atoms, when taken together with the nitrogen atom to which they are attached R.sup.1 and R.sup.2 form a substituted or unsubstituted heterocyclic group optionally containing an atom of oxygen, sulfur or a second atom of nitrogen as a ring member; their use as antihypertensive agents, pharmaceutical compositions containing them and intermediates for their production.

  2,4-二氨基喹唑啉的化学式为##STR1##，其中Y.sup.1为氢或氯，Y.sup.2为OR，Y.sup.3为氢或OR，当Y.sup.1为氢时，Y.sup.3为OR，当Y.sup.1为氯时，Y.sup.3为氢或OR，以及其药用盐；R代表一个具有一至三个碳原子的烷基基团；单独取R.sup.1和R.sup.2分别为氢、具有一至五个碳原子的烷基、具有三至八个碳原子的环烷基、具有三至五个碳原子的烯基或炔基，或具有两至五个碳原子的羟基取代的烷基，当与它们连接的氮原子一起时，R.sup.1和R.sup.2形成一个取代或未取代的杂环基团，该基团可选地含有一个氧原子、硫原子或第二个氮原子作为环成员；它们作为降压药剂的用途，含有它们的药物组合物以及它们生产的中间体。
• Molecular features of the prazosin molecule required for activation of Transport-P
  作者：Joaquim Fernando Mendes da Silva、Marcus Walters、Saad Al-Damluji、C. Robin Ganellin

  DOI：10.1016/j.bmc.2008.06.037

  日期：2008.8

  Closely related structural analogues of prazosin have been synthesised and tested for inhibition and activation of Transport-P in order to identify the structural features of the prazosin molecule that appear to be necessary for activation of Transport-P. So far, all the compounds tested are less active than prazosin. It is shown that the structure of prazosin appears to be very specific for the activation

  已经合成了哌唑嗪的紧密相关的结构类似物，并测试了其对Transport-P的抑制和激活，以鉴定似乎对于激活Transport-P必不可少的Prazosin分子的结构特征。到目前为止，所有测试的化合物都没有比哌唑嗪具有更高的活性。结果表明，哌唑嗪的结构似乎对激活非常特异。已发现仅喹唑啉可活化，并且6,7-二甲氧基和4-氨基的存在似乎至关重要。
• N-(2-benzimidazolyl)-piperazines
  申请人：Abbott Laboratories

  公开号：US04093726A1

  公开（公告）日：1978-06-06

  Disclosed are compounds of the formula ##STR1## wherein n is 2 or 3, R is hydrogen or methyl, R' is C.sub.1 -C.sub.6 alkyl, acyl, aryl, aroyl, alkoxycarbonyl, tetrahydrofuroyl, dialkylaminocarbonyl, or furoyl, and R" is hydrogen and methoxy. These compounds are useful as antihypertensive agents.

  本发明涉及一种具有以下结构式的化合物：##STR1## 其中n为2或3，R为氢或甲基，R'为C.sub.1-C.sub.6烷基、酰基、芳基、芳酰基、烷氧羰基、四氢呋喃基、二烷基氨基羰基或呋喃基，R"为氢和甲氧基。这些化合物可用作降压药。
• Antihypertensive agents
  申请人：Abbott Laboratories

  公开号：US04044135A1

  公开（公告）日：1977-08-23

  Described are the compounds 2[4(tetrahydro-2-furoyl)-hexahydro-1,4-diazepinyl-1]-4-amino-6,7-dimethoxy quinazoline and pharmaceutically acceptable acid addition salts thereof. The compounds are useful as antihypertensive agents.

  所述化合物是2-[4-(四氢呋喃-2-酰基) -六氢-1,4-二氮杂环-1]-4-氨基-6,7-二甲氧基喹噁啉及其药学上可接受的酸盐。该化合物可用作降压剂。
• Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
  申请人：Pfizer Inc.

  公开号：US04351940A1

  公开（公告）日：1982-09-28

  2,4-Diaminoquinazolines of the formula ##STR1## wherein Y.sup.1 is hydrogen or chloro, Y.sup.2 is OR, Y.sup.3 is hydrogen or OR such that when Y.sup.1 is hydrogen, Y.sup.3 is OR and when Y.sup.1 is chloro, Y.sup.3 is hydrogen or OR, and the pharmaceutically acceptable salts thereof; R represents an alkyl group having from one to three carbon atoms; taken separately, R.sup.1 and R.sup.2 are each hydrogen, alkyl having from one to five carbon atoms, cycloalkyl having from three to eight carbon atoms, alkenyl or alkynyl each having from three to five carbon atoms or hydroxy substituted alkyl having from two to five carbon atoms, when taken together with the nitrogen atom to which they are attached R.sup.1 and R.sup.2 form a substituted or unsubstituted heterocyclic group optionally containing an atom of oxygen, sulfur or a second atom of nitrogen as a ring member; their use as antihypertensive agents, pharmaceutical compositions containing them and intermediates for their production.

  公式为 ##STR1## 的2,4-二氨基喹嗪，其中Y1为氢或氯，Y2为OR，Y3为氢或OR，当Y1为氢时，Y3为OR，当Y1为氯时，Y3为氢或OR，以及其药学上可接受的盐；R代表具有1至3个碳原子的烷基；分别取R1和R2为氢、具有1至5个碳原子的烷基、具有3至8个碳原子的环烷基、具有3至5个碳原子的烯基或炔基或具有2至5个碳原子的羟基取代的烷基，当它们与它们所连接的氮原子一起取用时，R1和R2形成一个取代或未取代的杂环基，可选地含有一个氧原子、硫原子或第二个氮原子作为环成员；它们作为降压剂的用途，包含它们的制药组合物和它们制备的中间体。